Tryptamine Therapeutics Limited (AU:TYP) has released an update.
Tryptamine Therapeutics Limited, an Australian biotech firm, has announced updates to its Securities Trading Policy and provided insights into its advancements in psilocin-based treatments. The company has shown promising results in a Phase 2a clinical trial for binge eating disorder, demonstrating significant reduction in episodes, and is now expanding trials to include fibromyalgia and irritable bowel syndrome. Investors and stakeholders are directed to the company’s website for the full policy and further information on its clinical programs.
For further insights into AU:TYP stock, check out TipRanks’ Stock Analysis page.
